Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001209191-21-061277
Filing Date
2021-10-21
Accepted
2021-10-21 17:04:38
Documents
1
Period of Report
2021-10-19

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6665
  Complete submission text file 0001209191-21-061277.txt   8072
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Issuer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O CASCADIAN THERAPEUTICS, INC. 3101 WESTERN AVE., SUITE 600 SEATTLE WA 98121
Business Address
Myers Scott Dunseth (Reporting) CIK: 0001356256 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-34207 | Film No.: 211337788